Apr 16, 2024 | Biosimilars, Cost Savings, Drug costs, Humira, MedBen Rx, Pharmacy, Prescription, Rx Costs, Savings
Last year, MedBen Rx announced a new program that would enable clients to purchase Idacio, a biosimilar version of the anti-inflammatory therapy Humira – a drug that typically costs between $6,000 and $12,000 per month depending on the dose – for under $1,000 per...
Apr 15, 2024 | Alternative Reimbursement Strategies, Benchmarks, Cost Savings, Fair market reimbursement, Savings
At the Private Employer Roundtable on April 11, Regional Sales Director Brooke Hupp highlighted alternative reimbursement strategies that reduce health care costs, including MedBen’s newest strategy, Fair Market Reimbursement (FMR). This innovative approach...
Apr 2, 2024 | Case Studies, Claims, Claims Management, Claims negotiation, Cost Savings, Forensic claims review, Savings
Claim savings don’t have to end with the PPO network discount. With MedBen’s forensic claims review services, savings are produced after network discounts are applied, but before claims are paid. As the case study below shows, while PPO network discounts alone...
Apr 1, 2024 | Benefits preservation, Comparative Effectiveness, Cost Savings, Drug costs, MedBen Rx, Pharmacy, Pharmacy Benefits Manager (PBM), Rx Costs, Savings, Specialty Drugs, Transparency
Employers are turning away from the “big three” pharmacy benefits managers to other PBMs that offer greater transparency and lower costs, says Wharton professor of health care management Lawton Robert Burns. As one of those alternatives, MedBen Rx is...
Mar 19, 2024 | Asthma, Blood pressure, Cholesterol, Chronic conditions, Cost Savings, Diabetes, Health care costs, Heart, Hypertension, MedBen WellLiving, Savings, Wellness, Wellness exam, Wellness screenings
The cost of five major chronic conditions, in physical and financial terms: Cardiovascular disease (CVD) is the leading cause of death in the United States, and cost the U.S. $407.3 billion between 2018 to 2019.Between 2017 and 2020, 10% of adults age 20 or...
Mar 5, 2024 | Appropriateness Solutions, Comparative Effectiveness, Cost Savings, Drug costs, MedBen Rx, Rx Costs, Savings, Value
At January’s Benefits Advisory Conference, MedBen President & CEO Kurt Harden observed that when the Food and Drug Administration (FDA) evaluates a new drug to be approved for sale, it has to be safe and effective, but not necessarily superior to...
